Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

  • Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others
  • Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion
  • Experienced team with a background in biotechnology and company building led by co-CEO’s Michael Krohn and Lukas Linnig
  • Paul Scholz, the principal inventor of G-dase E technology, joins as Head of Research and Development

Zwingenberg, Germany, 4 February 2025 – Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase® E nucleases.

Read more…